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Progressive myoclonus epilepsy type 1 (EPM1) is a neurodegenerative disease correlating with mutations of the cystatin B gene. Cystatin B is
described as a monomeric protein with antiprotease function. This work shows that, in vivo, cystatin B has a polymeric structure, highly resistant
to SDS, urea, boiling and sensitive to reducing agents and alkaline pH. Hydrogen peroxide increases the polymeric structure of the protein. Mass
spectrometry analysis shows that the only component of the polymers is cystatin B. EPM1 mutants of cystatin B transfected in cultured cells are
also polymeric. The banding pattern generated by a cysteine-minus mutant is different from that of the wild-type protein as it contains only
monomers, dimers and some very high MW bands while misses components of MW intermediate between 25 and 250 kDa. Overexpression of
wild-type or EPM1 mutants of cystatin B in neuroblastoma cells generates cytoplasmic aggregates. The cysteine-minus mutant is less prone to the
formation of inclusion bodies. We conclude that cystatin B in vivo has a polymeric structure sensitive to the redox environment and that
overexpression of the protein generates aggregates. This work describes a protein with a physiological role characterized by highly stable
polymers prone to aggregate formation in vivo.
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cysteine family of proteases [1–3]. Its biochemical properties
have been studied in depth and its activity characterized [4–6].
The crystal structure of the protein in complex with papain [7],
its domain-swapped dimeric [8] and tetrameric forms [9] have
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doi:10.1016/j.bbamcr.2007.08.007has been demonstrated, there is evidence implying that this may
not be the only function. Di Giaimo et al. [10], in rat, have
isolated a number of proteins interacting specifically with
CSTB, none of which is a protease. The interactors are cyto-
plasmic proteins involved in cytoskeletal function. Some of
them are expressed exclusively in neurons. A specific function
of CSTB in the central nervous system may correlate with a
recent observation by Riccio et al. [11] showing cell-specific
expression of CSTB in the cerebellum, restricted to Purkinje
cells and Bergmann glial fibers.
Additional evidence on multiple functions of CSTB comes
from the involvement of cystatins in cancer [12], inflammation
[13], native immunity [14] and from their presence in the
amyloid plaques of Alzheimer's, Parkinson's diseases and
spongiform encephalopathies [15]. Increased cystatins A and B
in the plaques of Alzheimer's and Parkinson's diseases, and of
patients suffering from senile dementia is a common finding and
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ly, proteins of the cystatin family are used as models for in vitro
studies of amyloid fiber structure [17–19] and Staniforth et al.
[20], Janowski et al. [8] and Sanders et al. [21] have determined
the 3D structure of highly stable domain-swapped dimers in
vitro. If polymerization of cystatins exists in vivo, it may be
important for function(s) other than the inhibition of proteinases.
The most studied pathology characterized by mutations of
the cstb gene is progressive myoclonus epilepsy of the
Unverricht–Lundborg type (EPM1) [22]. EPM1 is an autoso-
mal recessive disorder in which patients suffer from myoclonic
jerks, frequent tonic–clonic seizures, and progressive decline in
cognition [6]. The autoptic results of pathologists on the brain of
the deceased patients show neural degeneration in several areas
of the central nervous system with cerebellar damage and
serious alterations of the Purkinje cells [23]. Although the cstb
gene is responsible for the disease, recently, cases have been
described that carry mutations associated with genes located on
different chromosomes [6,24,25].
The most common mutation described in EPM1 patients is
the expansion of an unstable dodecamer in the cstb promoter
[26,27]. This sequence, repeated up to 75 times, is found in
homozygosis or in heterozygosis together with an allele carrying
one of the following point mutations. A G4R or Q71P substitu-
tion, three splice site mutations altering the intron–exonTable 1
Primers Sequence
5′ BamH1 cstb terminal primer TATGGATCCATGATGTGTG
3′ EcoRI cstb terminal primer CCGGAATTCTCAGAAGTA
5′ cstbQ71P GGGTGTTTCCACCCCTCC
3′ cstbQ71P GAGGGAGGGGTGGAAAC
3′ EcoRI cstb Δ68 ATAGAATTCTCACAAGTG
3′ EcoRI cstb ΔTC TAGGAATTCTCATGAGGG
3′ EcoRI cstb Δ64 TCAAGAATTCTCATTTTTC
5′ BamH1 cstb ΔE1 TATGGATCCTAGTGAAGT
5′ cstb V59Q CCAACTTCTTCATCAAGG
3′ cstb V59Q GCACACATTTTTCTTCGCC
3′ EcoRI cstb T87K CCGGAATTCTCAGAAGTA
5′ BamH1 cstb C3S CTATGGATCCATGATGTCT
5′ cstb C64S CGGCGAAGAAAAATCTG
3′ cstb C64S GGGGTTCAAACACCCTCA
5′ cstbV48D CCTTCAGGAGACAGGTAG
3′ cstbV48D CCTTGATGAAGAAGTTCC
5′ cstbV48A CCTTCAGGAGACAGGTAG
3′ cstbV48A GAAGAAGTTGGTGCCGG
5′ cstbG50A GGAGACAGGTAGTGGCC
3′ cstbG50A CCTTGATGAAGAAGTTGG
5′ BamH1 cstb G4R BssHII a GATCCATGATGTGTCG
3′ BamH1 cstb G4R BssHIIa CGCGCGACACATCATG
5′ cstbVG48/50A GGAGACAGGTAGCGGCC
3′ cstbVG48/50A CCTTGATGAAGAAGTTGG
5′ XhoI cstb terminal primer b TATCTCGAGGAATGATGT
5′ XhoI cstb G4Rb TATCTCGAGGAATGATGT
5′ XhoI cstbC3Sb TATCTCGAGGAATGATGT
5′ Nco1-HA-polylinker c CATGGCCTACCCCTACGA
3′ Nco1-HA-polylinkerc GATCGGCTCGAGCCCGGG
3′ XhoI cstb terminal primer CGATTCTCGAGTCAGAAG
a The two complementary sequences were annealed and inserted directly into the
b Primers for pEGFP-C1.
c The two complementary sequences were annealed and inserted directly into thejunctions of the gene, a translational stop codon at amino acid
position 68 (Δ68), and a frameshift at position 72, followed by a
termination codon at position 75 (Δtc) [6,28].
This work shows that CSTB has a polymeric structure in vivo
in human and rat cells and, when overexpressed, generates
cellular aggregates. We propose that the regulation of both
expression and polymerization ofCSTB is very critical for the cell
and that a deregulation event may induce neural degeneration.
1. Material and methods
1.1. Antibodies (abs)
Rabbit anti-CSTB polyclonal abs, Biogenesis; mouse anti-GAPDH
monoclonal abs (MAB374), Chemicon; mouse anti-HA (F-7) monoclonal abs
and rabbit anti-HA (Y11) polyclonal abs, Santa Cruz Biotechnology, HRP-
conjugated goat anti-mouse IgG and goat anti-rabbit IgG, Santa Cruz
Biotechnology; FITC-conjugated sheep anti-mouse abs F(ab′)2 fragment,
Sigma; CyTM5-conjugated donkey anti-rabbit abs F(ab′)2 fragment, Jackson;
10-nm gold-conjugated goat anti-mouse abs, Amersham.
1.2. Cell culture and transfection
The cells used were 293T (from human embryonic kidney) and SKNBE
(from human bone marrow neuroblastoma). The cells were grown in DMEM
medium supplemented with 10% foetal bovine serum, glutamine, penicillin/
streptomycin and Na-pyruvate at 37 °C in 5% CO2. SKNBE cells were
transfected with Lipofectamine Plus (GIBCO) and 293T cells with 165 μM PEIGCGCGC
GGTTAGCTC
CTC
ACCC
CACACATTTTTC
AGGTTCAAACA
TTCGCCGACATCAAC
CTCAACTTGAAG
TTGATCAGGGCGAAGAAAAATGTGTGC
CTGATCAACCTTGATGAAGAAGTTGGG
GGTTAGCTCATCGTGCTTTTCTTTGTCCTTCTGGTAAGAGG
GGCGCGCC
TGCACTTGAGGGTGTTTGAACCCC
AGTGCACAGATTTTTCTTCGCCG
ACGCCGGCACCAACTTCTTCATCAAGG
TGCCGGCGTCTACCTGTCTCCTGAAGG
CGGCCGGCACCAACTTCTTC
CCGCTACCTGTCTCCTGAAGG
GCCACCAACTTCTTCATCAAGG
TGGCGGCCACTACCTGTCTCC
GCCACCAACTTCTTCATCAAGG
TGGCGGCCGCTACCTGTCTCC
GTGGCGCGC
GTCGCGCGCCATCCG
CTGGCGCGCC
CGTGCCCGACTACGCCTCCCTCGGATCCGGTACCCGGGCTCGAGCC
TACCGGATCCGAGGGAGGCGTAGTCGGGCACGTCGTAGGGGTAGGC
TAGGTTAGCTCATCG
BamHI–BssHII sites of the pRK7-HA-cstb vector.
NcoI–BamHI sites of the pET16b vector (Novagen).
Fig. 1. Structural organization of cellular CSTB. Western blot analysis:
(A) protein extract from 293T cells lysed without (buffer 1, lanes 1 and 3) and
with (buffer 2, lane 2) 1% SDS and run in absence (lanes 1 and 2) and presence
(lane 3) of 50mMDTT. Stainingwith anti-CSTB abs. (B) Protein extract from cells
lysed in buffer 1. Stainingwith anti-CSTB abs: untreated (lane 1), preabsorbedwith
E. coli protein extract expressing human CSTB (lane 2) or E. coli protein extract
(lane 3). Lower panel: staining with anti-GAPDH abs. (C) Protein extract from
293T cells, transfected with the pRK7-HAvector containing rat cstb cDNA, lysed
in buffer 2. Staining with anti-HA(F-7) abs: untreated (lane 1), preabsorbed with
E. coli protein extract expressing rat HA-CSTB (lane 2) or E. coli protein extract
(lane 3). (D) The same protein extracts as in panel C incubated 1 h as indicated. No
reducing agents added. Staining with anti-HA(F-7) abs.
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Rat cstb cDNA was used in all transfection experiments.
1.3. Cell lysis
Cells were harvested and washed in PBS. Lysis was (1) under non-denaturing
conditions, in PBS containing 20% glycerol, 0.4 mM EDTA, 1 mM DTT, 0.5%
NP40, antiprotease and anti-phosphatase cocktail (Sigma) (buffer 1); (2) under
denaturing conditions, in PBS containing 1% SDS (buffer 2). The protein extracts
were boiled 10min and diluted in PBS containing antiprotease and anti-phosphatase
cocktail (Sigma), to a final concentration of 0.1%SDS. The samples were sonicated
and centrifuged 30 min at 13,000 rpm, 4 °C. The supernatants were stored at
−80 °C. Protein concentration was determined using the Bio-Rad Protein Assay.
1.4. Immunoprecipitation experiments
Immunoprecipitation was carried out as previously described [10].
1.5. Redox experiments
The protein extracts were from cells lysed in buffer 1. pH curve: 60 μg
protein extract was incubated 5 min on ice, in 100 mM Tris–HCl or 50 mM Na
carbonate/bicarbonate buffers at the indicated pH. GSH curve: 60 μg protein
extract was incubated 10 min at RT, in 100 mM Tris–HCl pH 7.5 with GSH at
the indicated concentrations. H2O2 curve: 60 μg protein extract was incubated
20 min at RT, in H2O2 at the indicated concentrations. The reaction was stopped
by addition of loading buffer (12 mM Tris–HCl pH 6.8, 5% glycerol, 1% SDS
and 0.02% bromophenol blue) with or without 50 mM β-METOH, as indicated.
1.6. SDS-free size exclusion chromatography
Approximately 400 μg protein extract from 293T cells lysed in buffer 1 was
loaded on Tricorn Superdex®75 PC 3.2/30 (Amersham) equilibratedwith 50mM
Tris–HCl pH 7.5 and run at a flow rate of 0.1 ml/min. 50 μl Fractions were
collected.
1.7. Protein identification by mass spectrometry
30 mg 293T protein extract was immunoprecipitated. The immunoprecip-
itate (ip) was loaded on gel without eluting from the gel beads. The bands were
excised from the gel, reduced, alkylated using iodoacetamide, and digested
with trypsin. The resulting fragments were extracted and analyzed by LC/MS on
a Q-Tof Premier instrument (Waters, Corporation, Milford, MA, USA) coupled
with a Waters 1065 HPLC apparatus (Waters Corporation). Peptides separation
was carried out on a Proteus C18 (100×1 mm) column (Phenomenex, Foster
City, CA, USA) using a linear gradient from 5% to 60% of 1% formic acid,
0.05% trifluoroacetic acid in CH3CN over 50 min (flow rate 50 μl/min). Mass
spectra were acquired over a m/z range from 400 to 2000. The resulting
fragments were extracted, purified using C18 ZipTip (Millipore) and measured
by MALDI-TOF mass spectrometry on a Biflex instrument (Bruker, Bremen).
1.8. Site-directed mutagenesis
WT and mutant CSTB sequences were inserted in the pRK7 vector
containing one copy of the hemagglutinin tag sequence (pRK7-HA) upstream
from the BamHI site. The recombinants were inserted between the BamHI and
EcoRI sites. Mutagenesis was carried out by PCR amplification using the
primers indicated in Table 1. wt and mutant sequences were inserted between the
XhoI and EcoRI sites of the pEGFP-C1 vector (BD Biosciences Clontech). The
pET16b-HA vector was generated from the pET16b vector (Novagen) by
insertion of the hemagglutinin sequence upstream the insertion site.
1.9. Bacterial protein extracts
Escherichia coli BL21 (DE3) cells were transformed by electroporation and
induced for 3 hwith 0.5mMIPTG(Sigma) before harvesting and lysing in buffer 1.1.10. Preabsorption experiments
Anti-CSTB abs (at a final concentration of 24 μg/ml) or anti-HA(F-7) abs (at
a final concentration of 0.28 μg/ml) were mixed with the protein extract from
BL21 cells (with or without CSTB) at the final concentration of 9.5 mg/ml.
Following a 1-h incubation at RT the protein extracts were centrifuged 10 min at
13,000 rpm. The supernatants were collected and analyzed by Western blot. The
immunostaining was with anti-CSTB or -HA abs.
Immunofluorescence analysis, confocal microscopy, co-localization analysis
and transmission electron microscopy were carried out as previously described
[11,29].2. Results
2.1. Cellular CSTB has a polymeric structure
The structural organization of endogenous (human) and
transfected (rat) CSTB in the 293T cell line is analyzed in Fig. 1.
The expected molecular weight (MW) for CSTB is approxi-
mately 12 kDa. In the absence of DTT, a complex pattern of
Fig. 2. SDS-free size exclusion chromatography of CSTB from a native protein
extract of 293Tcells analyzed on a Tricorn Superdex®75 column: fractions from
the column loaded on SDS Laemmli gel without reducing agents and analyzed
by Western blot. Fraction 17 contains the excluded peak of the column and from
19 onward the separation starts. (A) The size distribution of the proteins stained
with Poinceau red shows the expected separation of the molecular weights in
fractions 19–30. (B) Western blot stained with anti-CSTB abs.
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lysates, with a similar distribution and intensity. The reducing
condition increases the intensity of the 12-kDa band although
some of the polymers are still detectable. To make sure that the
high molecular weight components were real and not due toFig. 3. Mass spectrometry analysis of the CSTB polymers. (A) Ip with anti-HA(F-7)
sample. Gel stained with colloidal brilliant blue G (Sigma). Numbers on the right ind
peptide within the CSTB sequence is shown. H refers to human and R to rat CSTBantibody background, we have checked the antibody specificity
by preabsorption experiments. B shows that preabsorption of
the anti-CSTB abs with human CSTB, synthesised in E. coli,
cancels the endogenous signal. The same is true in C, where the
293T cells were transfected with rat HA-CSTB and preabsorp-
tion was carried out with rat HA-CSTB synthesised in E. coli.
These results confirm the presence, in vivo, of a polymeric
structure resistant to SDS denaturation (lane 2A) and sensitive
to DTT treatment (lane3A) which may represent either co- or
homopolymers of CSTB. The same polymeric pattern was
obtained analyzing rat PC12 and B104 cells, human SKNBE
and HeLa cells and, interestingly, E. coli transformed with a
CSTB expressing construct (not shown). It should be noticed
that E. coli does not express cystatin-like proteins and rep-
resents a background free system. Treatment with 8 M urea
before SDS-PAGE does not denature CSTB polymers (panel
D), although a few bands, in the intermediate molecular weight
range, are no longer detectable. We conclude that the polymeric
structure of CSTB is resistant to denaturation in 1% SDS and
8 M urea, and partially resistant to reducing agents. For
simplicity, we will call “CSTB polymers” all CSTB high
molecular weight species resistant to denaturation.
The native size of the high molecular mass CSTB com-
ponents was examined submitting the protein extract from 293T
cells to size fractionation (Fig. 2). The Western blot analysis of
the fractions stained with anti-CSTB abs shows that low MW
components, mainly monomers, are in fractions 21–30 (panel
B). Fractions 27–30 correspond to the approximate MW of the
CSTB monomer, dimer and trimer, suggesting that a small
amount of CSTB is not bound to other proteins. Monomeric
CSTB in fractions 21–26 is probably released from its
interaction with cellular proteins upon SDS boiling and SDS-
PAGE. In fact, native CSTB interacts with a number of proteins
that increase its size on fractionation [10]. Polymeric CSTB is
detectable in fractions 17–20, corresponding to the excluded
peak of the column. The presence of the entire band ladder in the
excluded region suggests that also the polymers interact withabs from the same protein extract as in Fig. 1C. No reducing agents added to the
icate the analyzed bands. (B) Mass spectrometry analysis. The position of each
.
Fig. 5. Transfection of CSTB mutants in 293T cells lysed in buffer 2. Ip with
anti-HA(F-7) abs of protein extracts from 293T cells transfected with wt and
mutant constructs indicated under the lanes. NT refers to non-transfected cells.
SDS polyacrylamide gels run minus (A) and plus (B) 200 mM DTT. Staining
with anti-HA(Y11) abs. The dotted line indicates the position of the stacking
region of the gel.
Fig. 4. Effect of pH, reducing and oxydising agents on CSTB polymers from
293T cells lysed in buffer 1. Staining with anti-CSTB abs. Lower panels in A
and B: staining with anti-GAPDH abs. 60 μg protein extract were loaded on
each lane. (A) pH curve as indicated. No reducing agents added to the samples.
(B) Samples treated with increasing concentrations of GSH as indicated. No
reducing agents added to the samples. (C) Samples treated with increasing
concentrations of H2O2 as indicated. Lanes 1–4: minus reducing agents, lanes
5–8: plus reducing agents.
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in the cells and is eluted in the excluded volume of the column;
(2) protein interactions occur mainly with polymeric CSTB. The
clear separation between low and high molecular mass
components, present in different fractions of the column,
shows that polymerization of CSTB is not an artefact due to
SDS or self-assembly.
To distinguish between homo- and heteropolymers, the SDS
denatured immunoprecipitated CSTB was analyzed by in geldigestion and mass spectrometry. The SDS-PAGE is shown in
Fig. 3. The bands indicated in A were analyzed and the
experimental results were compared to the theoretical molecular
mass values (panel B). Bands 1, 2, 3 migrate at the position of
endogenous and transfected monomers. Bands 4 and 5 migrate
as homo- and hetero-trimers and band 6 as a pentamer. Protein
modifications are not detectable although monomer, dimer and
trimer migrate in multiple bands within the range of approxi-
mately 2 kDa. We envisage two possible reasons for this: (1) the
N-terminal region of the protein (fragments 1–24) was not
identified by mass spectrometric analysis, therefore the presence
of modifications within the first 24 aa cannot be excluded. (2)
The structure of the protein is unstable and shows conforma-
tional changes [19,30,31]. The identity between the experimen-
tal and theoretical molecular mass values confirms that the bands
contain CSTB only, and that their position in the denaturing gel
is not due to the interaction with other proteins. As we have
transfected human 293T cells with rat CSTB and the rat and
human sequences are different, we can distinguish the endog-
enous human from the transfected rat molecules (panel B and
Fig. 6A). Both species are in polymeric andmonomeric form and
this can be explained by the interaction between endogenous and
transfected CSTB that can be partially denaturated by boiling.
We conclude that SDS-resistant CSTB polymers are not due to
covalent interaction with proteins different from itself and that
CSTB forms homopolymeric structures.
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treatmentwith reducing/oxydising agents. The effect of increasing
pHon the polymeric structure is shown in panelAwhere polymers
are barely detectable at pH 9.8. Glutathione at a concentration
2.5–20mM decreases but does not eliminate the highMWCSTB
bands (panel B). The effect of these treatments suggests that
CSTB polymers are somewhat resistant to denaturation and that a
combination of reducing and denaturing conditions are necessary
to depolymerize the protein. Panel C shows the effect of H2O2
addition to a protein extract from 293Tcells. As the concentration
of H2O2 increases, we observe first an increase of the dimer band,
followed by the trimer that becomes the dominant species at 1 M
H2O2. This result suggests that, under oxydising conditions, the
trimeric structure of CSTB is very stable. Under reducing
conditionsmonomers are released from the highMWcomponents
up to a concentration of 0.8 M H2O2. The sample treated with
1.0 M H2O2 shows considerable resistance to denaturation of the
trimer and of higher MW components suggesting the existence of
irreversible hyperoxydated species, carrying sulphonylated,
carbonylated or nitrated residues [32,33].
2.2. The cysteine-minus mutants of CSTB
The reactive thiol groups fulfil a sensory and regulatory role
on proteins, in response to a defined redox environment. Most
CSTB, including the humanmolecule, contain only one cysteine
at position 3, while rodent CSTB has an additional cysteine at
position 64 [4]. The phylogenetic conservation of Cys3 and the
sensitivity of the high molecular weight species to the redox
environment suggest that at least one cysteine is important.
Thus, we have analyzed the structure of single and double
cysteine substitution mutants of rat CSTB. The ips from protein
extracts of cells transfected with these constructs are in Fig. 5,
panels A and B. The banding pattern of the single substitution
mutants is similar to that of the wt protein suggesting that the two
cysteines present in the rat molecule are interchangeable. InFig. 6. Transfection of CSTB mutants in 293T cells lysed in buffer 2.
(A) Structure of wt and mutant rat CSTB constructs. The vertical lines in the wt
scheme indicate the position of amino acids which differ between rat and man.
The asterisks indicate the position of the amino acid substitutions in the mutants.
The dotted lines indicate the position of the phylogenetically conserved motives
shown above. The mutants were constructed using the cystatin sequence
alignments published by Rawlings and Barrett [4]. The natural mutants were
G4R, Q71P,Δ68 andΔtc. Additional truncation mutants were Δ64 (stop codon
at position 64) and ΔE1 (deletion of exon 1 encoding aa 1–22). Staniforth et al.
[20] have shown that the chicken cystatin mutant I66Q forms dimers while the
I102K generates monomers only. The I66Q is the chicken equivalent of human
L68Q, from patients affected by the Icelandic type of amyloidosis [34].
Although CSTB and C belong to different families of cystatins, their
phylogenetic conservation allows the construction of equivalent mutants for
the two species. V59Q and T87K (panel A) are derived from I66Q and I102K
mutants respectively. (B, C) Ip with anti-HA(F-7) abs of protein extracts from
293T cells transfected with wt and mutant constructs indicated under the lanes.
NT refers to non-transfected cells. SDS polyacrylamide gels run minus (B) and
plus (C) 200 mM DTT. Staining with anti-HA(Y11) abs. Panels B and C are a
pool of different experiments, each one carried out with its own NT and wt
controls. (D) Protein extracts from 293T cells transfected with single and
multiple substitution mutants of loop I. No reducing agents added to the
samples. Staining with anti-HA (F-7) abs. The dotted line indicates the position
of the stacking region of the gel.
Fig. 7. Expression of CSTB. 24-h transfection of SKNBE cells withwt andmutant
CSTB constructs: Confocal microscopy analysis of SKNBE cells transfected with
wt and mutant CSTB as indicated: point mutations and cysteine substitution
mutants are stained with anti-CSTB and anti-HA abs. Colocalization is shown.
Scale bar: 5 μm.
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in addition to high MW polymers stacked in the high portion of
the gel. The oligomers in the middle MW range are barely
detectable. The addition of 200 mM DTT (B) to C3S, C64S and
wt CSTB decreases the amount of protein in the stacking gel and
releases components migrating in the middle MW range. The
ΔCys mutant does not respond to DTT addition. We can con-
clude that cysteines are not necessary to form dimers, and that
neither the phylogenetically conserved Cys 3 nor Cys 64 is
necessary to the formation of high MW species. However, re-
active thiol groups seem to be important to stabilize the inter-
mediateMW species which are clearly visible and stable when at
least one cysteine is present in the sequence. CSTA and chicken
cystatin dimers generated in vitro by 3D domain swapping have
been described by Staniforth et al. [20] as the initial step to the
formation of amyloid fibers. Since CSTA belongs to the same
family as CSTB, the dimer that we observe in vivo may have a
similar origin, implicating hydrophobic interactions.
2.3. Structural organization of CSTB natural EPM1 mutants
We have analyzed the structural organization of a number of
CSTB mutants including those isolated from EPM1 patients
(Fig. 6). In vivo all CSTB mutants generate high MW structures
(panel B). Differences in the banding patterns are mainly due to
the different MW of the constructs. In agreement with the
experiments shown in Fig. 5, the addition of 200 mM DTT is
not sufficient to depolymerize CSTB completely (panel C).
Both carboxyl- and amino-terminus deletion mutants seem to
polymerize very efficiently. Accordingly, fast fibrillation of the
N-terminal fragment in comparison to the wild type was ob-
served by Rabzelj et al. [35]. In contrast to the results obtained
by Staniforth et al. [20], the V59Q and T87K substitutions
generate high MW components, suggesting a difference be-
tween the two polymerization processes.We conclude that none
of the mutations analyzed interferes with the process of poly-
merization of CSTB in vivo.
According to Staniforth et al. [20], aa substitutions in the
QVVAG loop of cystatins do not allow polymerization of the
molecule. We have generated single and double substitution
mutants of this region to see whether in vivo polymerization
requires the integrity of loop I. The mutant V48D corresponds
to the chicken mutant V55D of Staniforth et al. [20]. We have
also mutated amino acids at the most highly conserved sites of
the QVVAG loop: V48A, G50A and VG48/50A. The sub-
stitutions at aa positions 48 and 50 were also inserted in the
cysteine-minus constructs (ΔCys/V48A and ΔCys/G50A). The
distribution of the CSTB bands in all mutants is similar to that of
the wt protein with the exception of the cysteine-minus con-
structs that show monomers, dimers and bands larger than
250 kDa as dominant species, while the intermediate forms are
barely detectable (panel D).
We conclude that aa substitutions in loop I do not alter the
polymerizing capacity of CSTB in vivo. These results, in con-
trast with those obtained by Staniforth et al. [20] in vitro, may
be due to the presence, in vivo, of chaperon or other proteins
involved in the polymerization process [36].2.4. Expression of CSTB and its mutants in SKNBE cells
Since 293T cells tend to form foci during growth and are
detached from the plate surface by the fixation procedure,we have
chosen SKNBE neuroblastoma cells for microscopic analysis.
The phenotype induced by expression of rat CSTB and itsmutants
in SKNBE cells was analyzed by immunofluorescence confocal
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transfected and non-transfected SKNBE cells. The localization of
the protein is mainly nuclear although it is detectable also in the
cytoplasm [28,37]. Following 24-h transfection, the localization
of the substitution mutants is similar to that of wt rat CSTB. In
contrast, the carboxy- and amino-terminus deletion mutants show
a different distribution: the staining with anti-HA abs is barely
detectable in the nuclear compartment and is strong in the
cytoplasm (Fig. 8). Furthermore, the signal is concentrated in
randomly distributed aggregates of variable size and number,
similar to the cytoplasmic inclusion bodies described by Rajan
et al. [49]. In some cases the aggregates are numerous and small
(Δ68), in other cases we see large aggregates which may result
from the confluence of small ones (Δ64 and ΔE1). In agreement
with the nuclear presence of the endogenous protein, the same
cells are stained by the anti-CSTB abs both in the nucleus and in
the cytoplasm, and aggregated forms are also detected.
The EM analysis of cells transfected 24 h with rat wt CSTB
and two deletion mutants is shown in Fig. 9. In agreement with
our previous data [37], wt CSTB does not coincide with defined
cellular structures. The gold particles show a regular distribution
in the nucleus and in the cytoplasm, outside of the known
cellular organelles. The pattern generated by the Δ68 and Δtc
mutants is different from that of wt CSTB. The protein appears
highly concentrated in some regions of the cytoplasm. The
alignment of granules that we have observed in numerous ag-
gregate containing cells is interesting [38]. The other deletion
mutants analyzed showed a similar cellular distribution of CSTB
(not shown).
We have carried out a time course of transfection up to 7 days
in order to study the rate of aggregate formation throughout thisFig. 9. EM analysis of SKNBE cells transfected with wild-type and two CSTB
natural mutants as indicated. N: nucleus; arrows: mitochondria; rectangles:
regions shown on the right in 5× magnification; scale bar: 1 μm.
Fig. 8. Expression of CSTB. 24-h Transfection of SKNBE cells with deletion
mutants of CSTB as indicated. Confocal microscopy analysis as in Fig. 7.period (Fig. 10). The ΔCys mutant, that seemed to modify the
polymerization pattern of CSTB, and two natural EPM1
mutants were chosen for this experiment. The proportion of
transfected cells is relatively constant up to 7 days when, in
most samples, a decrease, possibly due to death, is detectable.
The green fluorescent protein (EGFP) alone does not produce
aggregates up to 7 days after transfection (panel A). The wt
CSTB fusion construct starts generating aggregates 48 h after
transfection and the number of positive cells increases gradually
for 7 days, when approximately 40% of the transfected cells
contain CSTB inclusions (panel B). The G4R mutant shows a
steeply growing curve where, from days 5 to 7, 70–90% of the
transfected cells contain aggregates (panel C). Twenty-four
hours after transfection, the Δ68 fusion generates aggregates
already in 20% of the cells (panel D). At day 5 almost 100% of
the cells contain aggregates. The ΔCys fusion does not produce
detectable aggregates until day 7, when approximately 30% of
the transfected cells are affected (panel E). This result is inter-
esting as we have seen that ΔCys is the only mutant altering the
polymerization pattern of CSTB (Fig. 5). The delayed appear-
ance of aggregates could be due to the presence of endogenous
Fig. 10. Time course of transfection of SKNBE cells with pEGFP fusion constructs of wt and mutant CSTB. The percentage of cells containing CSTB aggregates is
calculated as the ratio between aggregate containing and transfected cells and shown on the left. The statistical significance of the differences between the experimental
points was evaluated by Student's t-test. Fluorescent aggregates generated by the CSTB fusion proteins are shown on the right of the histograms. The transfected
constructs are indicated over each histogram. scale bar: 5 μm.
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tion. In fact, human CSTB contains the cysteine that may be
important in aggregate formation.
3. Discussion
CSTB belongs to a highly conserved family of antiproteases,
some of which have been associated with amyloidosis. So far,
CSTB has been described as a protein monomeric in vivo and
prone to amyloid fiber formation in vitro [17]. Manning and
Colòn [39] have described a number of proteins characterized by
high kinetic stability and resistance to SDS denaturation with a
structure containing disulfide bonds, oligomeric interfaces and
bound metals. These features are present in CSTB polymers that
bind copper as well ([40], R. Di Giaimo, E. Cipollini, M. Melliunpublished observation). The exceptional resistance of CSTB
polymers to SDS and 8M urea and the response to modifications
of the redox conditions [32] are similar to those shown by
oligomers from amyloid plaques of Alzheimer's disease patients
[41].
The SDS-free size fractionation column of the native protein
extract confirms the presence in the cell of polymers containing
CSTB. A protein that interacts with partners of different MW in
a native extract does not reflect the size of the protein itself. In
fact, the prevalence of monomers in the linear part of the
column and of variable size polymers in the high MW fractions,
is in agreement with the interaction of CSTB with different
proteins. In addition, the Western blot analysis shows clearly the
presence in the excluded peak of the column, of SDS resistant
CSTB polymers separate from monomers and dimers and the
321E. Cipollini et al. / Biochimica et Biophysica Acta 1783 (2008) 312–322mass spectrometry analysis shows that they are homopolymers
[42,43].
Several authors have suggested that oligomerization through
3D domain swapping may represent an important step on the in
vitro generation of oligomers [44–47]. Staniforth et al. [20] and
Kokalj et al. [9] have proposed a model of in vitro growth by
dimeric addition for cystatin amyloid fibers. We find that CSTB
polymers in vivo grow by monomer addition. We can conclude
that the process of polymerization in vivo and in vitro is
different. The presence, in vivo, of chaperon-like and/or redox
response proteins may be important to this process [32,36].
A diagnostic marker of amyloid fibers is the birefringence on
polarized light, following congo red staining [19]. CSTB
aggregates, stained with congo red, do not show this effect in
24-h transfection, suggesting that they do not contain amyloid
fibers (not shown). It is worth noting that many prion diseases
lack cerebral plaques that stain with amyloid specific dyes [48].
Cytoplasmic inclusion bodies have been described by Rajan
et al. [49]. These aggregates are called aggresomes when they
localize near the microtubule organizing center, through a pro-
cess mediated by a dynein/dynactin retrograde transport. Our
results do not allow a distinction between the two types of
protein inclusions as their cellular localization seems to be
variable. However, both types of aggregates are described in
neurodegenerative disorders such as Parkinson's, Alzheimer's,
ALS and Pick's diseases [50].
A regulatory role of cysteine(s) on the stability of the
intermediate MW components, together with the evidence on
the toxicity of oligomers in neurodegeneration, correlates with
the late appearance of aggregates in cells transfected with the
cysteine-minus mutant (Fig. 10) [41,48,53,54]. Amyloid-like
proteins in yeast are physiological [55,56] and Berson et al. [57]
have shown that amyloid-like fibril formation is physiological
in man as well. E. coli and Salmonella form amyloid-like
extracellular fibrils orchestrated by two different operons [58].
In synthesis, we may say that fibril formation is an evolutionary
conserved mechanism for creating biologically active quater-
nary structures [59]. We propose that polymeric CSTB can also
be classified as a protein whose properties are beneficial to the
cell but prone to toxic aggregate formation when overexpressed.
Finally, our results suggest that the neurodegeneration
observed in EPM1 patients heterozygous for both promoter
and point mutations is caused by the expression of the mutant
protein which is stable and tends to generate aggregates. This is
in agreement with a previous suggestion by Rabzelj et al. [35]
and Ceru et al. [60]. On the other hand, previous work casts
doubts on the absence of antiprotease activity as a cause of
EPM1 [24,51]. As CSTB interacts with a number of cytoskeletal
proteins, we have proposed a cytoskeletal function for it [10,11]
which may be important in neuronal signal transmission [52].
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